SCHEMBL6255175

SCHEMBL6255175

N#Cc1c(N)nc2sc(C(N)=O)c(N)c2c1-c1ccco1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.65
MAPT P10636 3/20 0.60
USP2 O75604 1/20 0.60
HTT P42858 1/20 0.60
PTK2B Q14289 1/20 0.60
HSD17B10 Q99714 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
EEF2K O00418 7/20 0.59
HSP90AB1 P08238 1/20 0.57
IKBKB O14920 1/20 0.57
LIMK1 P53667 1/20 0.55
ADORA3 P0DMS8 2/20 0.53
ADORA1 P30542 2/20 0.53
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.52
LMNA P02545 1/20 0.52
RECQL P46063 1/20 0.52
RAB9A P51151 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14954758 0.91 BRAF (0.53) BRAFMAPTUSP2HTTPTK2B
SCHEMBL1539825 0.88 MEN1 (0.66) BRAFMAPTUSP2HTTPTK2B
SCHEMBL1539792 0.86 BRAF (0.58) BRAFMAPTUSP2HTTPTK2B
SCHEMBL14955303 0.85 MEN1 (0.65) BRAFMAPTUSP2HTTHSD17B10
SCHEMBL192321 0.83 MAPT (0.59) BRAFMAPTUSP2HTTHSD17B10
SCHEMBL18537584 0.82 ALDH1A1 (0.56) MAPTUSP2HTTHSD17B10ADORA3
SCHEMBL1775711 0.82 BRAF (0.81) BRAFMAPTUSP2HTTHSP90AB1
SCHEMBL3092223 0.82 BRAF (0.64) BRAFMAPTUSP2HTTHSD17B10
SCHEMBL3101766 0.81 EEF2K (0.62) BRAFMAPTUSP2HTTEEF2K
SCHEMBL6252769 0.80 BRAF (0.71) BRAFMAPTUSP2HTTEEF2K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005058315-A1 NOVEL HETEROCYCLIC COMPOUNDS AS IKK2 INHIBITORS WITH ANTI-HBV ACTIVITY RIBAPHARM, INC. (US) 2005-06-30 WO disclosed